Compass Therapeutics, Inc. (NASDAQ: CMPX) Stock Competitors & Peer Comparison
See CMPX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CMPX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CMPX | $2.08 | +0.48% | 374.6M | -5.07 | -$0.41 | N/A |
| VRTX | $479.00 | +0.34% | 121.6B | 25.45 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $667.17 | +1.70% | 68.7B | 14.62 | $45.63 | +0.54% |
| ARGX | $888.82 | -3.20% | 55.3B | 80.22 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $188.07 | -0.61% | 40B | -26.60 | -$7.07 | N/A |
| RVMDW | $9.55 | +0.53% | 39.8B | -2.27 | -$4.15 | N/A |
| ALNY | $278.40 | +2.44% | 37.2B | 50.16 | $5.55 | N/A |
| ONC | $325.90 | +0.00% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
CMPX vs VRTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, VRTX has a market cap of 121.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while VRTX trades at $479.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas VRTX's P/E ratio is 25.45. In terms of profitability, CMPX's ROE is -0.40%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, CMPX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
CMPX vs VRNA Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CMPX's ROE is -0.40%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, CMPX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
CMPX vs REGN Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, REGN has a market cap of 68.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while REGN trades at $667.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas REGN's P/E ratio is 14.62. In terms of profitability, CMPX's ROE is -0.40%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CMPX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
CMPX vs ARGX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ARGX trades at $888.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ARGX's P/E ratio is 80.22. In terms of profitability, CMPX's ROE is -0.40%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, CMPX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
CMPX vs SGEN Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CMPX's ROE is -0.40%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CMPX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
CMPX vs RVMD Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, RVMD has a market cap of 40B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while RVMD trades at $188.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas RVMD's P/E ratio is -26.60. In terms of profitability, CMPX's ROE is -0.40%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, CMPX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
CMPX vs RVMDW Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, RVMDW has a market cap of 39.8B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while RVMDW trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas RVMDW's P/E ratio is -2.27. In terms of profitability, CMPX's ROE is -0.40%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, CMPX is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
CMPX vs ALNY Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ALNY has a market cap of 37.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ALNY trades at $278.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ALNY's P/E ratio is 50.16. In terms of profitability, CMPX's ROE is -0.40%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, CMPX is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
CMPX vs ONC Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ONC trades at $325.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ONC's P/E ratio is 72.91. In terms of profitability, CMPX's ROE is -0.40%, compared to ONC's ROE of +0.12%. Regarding short-term risk, CMPX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
CMPX vs ROIV Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ROIV trades at $34.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ROIV's P/E ratio is -35.69. In terms of profitability, CMPX's ROE is -0.40%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, CMPX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
CMPX vs INCY Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, INCY has a market cap of 23.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while INCY trades at $118.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas INCY's P/E ratio is 15.98. In terms of profitability, CMPX's ROE is -0.40%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CMPX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
CMPX vs BNTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while BNTX trades at $91.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas BNTX's P/E ratio is -19.72. In terms of profitability, CMPX's ROE is -0.40%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, CMPX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
CMPX vs INSM Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, INSM has a market cap of 22.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while INSM trades at $104.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas INSM's P/E ratio is -18.21. In terms of profitability, CMPX's ROE is -0.40%, compared to INSM's ROE of -1.30%. Regarding short-term risk, CMPX is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
CMPX vs UTHR Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while UTHR trades at $527.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas UTHR's P/E ratio is 19.49. In terms of profitability, CMPX's ROE is -0.40%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CMPX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
CMPX vs MRNA Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, MRNA has a market cap of 22.1B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while MRNA trades at $55.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas MRNA's P/E ratio is -6.83. In terms of profitability, CMPX's ROE is -0.40%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, CMPX is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
CMPX vs BGNE Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CMPX's ROE is -0.40%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, CMPX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
CMPX vs DNA-WT Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CMPX's ROE is -0.40%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CMPX is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
CMPX vs NBIX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while NBIX trades at $176.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas NBIX's P/E ratio is 25.49. In terms of profitability, CMPX's ROE is -0.40%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, CMPX is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check NBIX's competition here
Genmab A/S (NASDAQ: GMAB)
CMPX vs GMAB Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while GMAB trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas GMAB's P/E ratio is 20.72. In terms of profitability, CMPX's ROE is -0.40%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, CMPX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check GMAB's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
CMPX vs BBIO Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while BBIO trades at $84.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas BBIO's P/E ratio is -22.49. In terms of profitability, CMPX's ROE is -0.40%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, CMPX is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
CMPX vs JAZZ Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while JAZZ trades at $255.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas JAZZ's P/E ratio is 19.86. In terms of profitability, CMPX's ROE is -0.40%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, CMPX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
CMPX vs ASND Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ASND trades at $253.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ASND's P/E ratio is -104.72. In terms of profitability, CMPX's ROE is -0.40%, compared to ASND's ROE of -56.42%. Regarding short-term risk, CMPX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
CMPX vs EXEL Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while EXEL trades at $55.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas EXEL's P/E ratio is 16.71. In terms of profitability, CMPX's ROE is -0.40%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, CMPX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check EXEL's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
CMPX vs MDGL Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, MDGL has a market cap of 12.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while MDGL trades at $551.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas MDGL's P/E ratio is -43.07. In terms of profitability, CMPX's ROE is -0.40%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, CMPX is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
CMPX vs KRTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CMPX's ROE is -0.40%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CMPX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check KRTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
CMPX vs AXSM Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, AXSM has a market cap of 12.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while AXSM trades at $238.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas AXSM's P/E ratio is -62.24. In terms of profitability, CMPX's ROE is -0.40%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, CMPX is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
CMPX vs ARWR Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ARWR has a market cap of 12B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ARWR trades at $85.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ARWR's P/E ratio is -39.78. In terms of profitability, CMPX's ROE is -0.40%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, CMPX is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CMPX vs BMRN Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while BMRN trades at $60.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas BMRN's P/E ratio is 28.98. In terms of profitability, CMPX's ROE is -0.40%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, CMPX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
CMPX vs RNAM Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CMPX's ROE is -0.40%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CMPX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
CMPX vs TECH Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while TECH trades at $71.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas TECH's P/E ratio is 36.91. In terms of profitability, CMPX's ROE is -0.40%, compared to TECH's ROE of +0.05%. Regarding short-term risk, CMPX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check TECH's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
CMPX vs KRYS Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, KRYS has a market cap of 10.4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while KRYS trades at $351.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas KRYS's P/E ratio is 47.03. In terms of profitability, CMPX's ROE is -0.40%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CMPX is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check KRYS's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
CMPX vs SMMT Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while SMMT trades at $13.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas SMMT's P/E ratio is -8.19. In terms of profitability, CMPX's ROE is -0.40%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, CMPX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for CMPX.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
CMPX vs CYTK Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CYTK trades at $80.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CYTK's P/E ratio is -13.83. In terms of profitability, CMPX's ROE is -0.40%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, CMPX is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CYTK's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
CMPX vs HALO Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while HALO trades at $81.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas HALO's P/E ratio is 17.64. In terms of profitability, CMPX's ROE is -0.40%, compared to HALO's ROE of +1.26%. Regarding short-term risk, CMPX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
CMPX vs RXDX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CMPX's ROE is -0.40%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CMPX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
CMPX vs ABVX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ABVX has a market cap of 9.4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ABVX trades at $128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ABVX's P/E ratio is -67.09. In terms of profitability, CMPX's ROE is -0.40%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CMPX is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
CMPX vs IONS Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while IONS trades at $55.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas IONS's P/E ratio is -32.53. In terms of profitability, CMPX's ROE is -0.40%, compared to IONS's ROE of -0.59%. Regarding short-term risk, CMPX is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check IONS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
CMPX vs NUVL Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas NUVL's P/E ratio is -21.79. In terms of profitability, CMPX's ROE is -0.40%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CMPX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
CMPX vs KYMR Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while KYMR trades at $110.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas KYMR's P/E ratio is -31.18. In terms of profitability, CMPX's ROE is -0.40%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, CMPX is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
CMPX vs CRNX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CRNX trades at $83.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CRNX's P/E ratio is -16.35. In terms of profitability, CMPX's ROE is -0.40%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CMPX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CRNX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
CMPX vs PRAX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, PRAX has a market cap of 8.8B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while PRAX trades at $315.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas PRAX's P/E ratio is -23.62. In terms of profitability, CMPX's ROE is -0.40%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, CMPX is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check PRAX's competition here
Alkermes plc (NASDAQ: ALKS)
CMPX vs ALKS Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ALKS trades at $52.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ALKS's P/E ratio is 55.51. In terms of profitability, CMPX's ROE is -0.40%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, CMPX is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ALKS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
CMPX vs IMGN Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CMPX's ROE is -0.40%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CMPX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
CMPX vs PTGX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while PTGX trades at $135.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas PTGX's P/E ratio is -74.90. In terms of profitability, CMPX's ROE is -0.40%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, CMPX is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check PTGX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
CMPX vs SYRE Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, SYRE has a market cap of 8.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while SYRE trades at $100.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas SYRE's P/E ratio is -48.10. In terms of profitability, CMPX's ROE is -0.40%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, CMPX is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
CMPX vs TGTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while TGTX trades at $55.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas TGTX's P/E ratio is 19.16. In terms of profitability, CMPX's ROE is -0.40%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, CMPX is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
CMPX vs BPMC Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CMPX's ROE is -0.40%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CMPX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
CMPX vs APGE Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while APGE trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas APGE's P/E ratio is -31.01. In terms of profitability, CMPX's ROE is -0.40%, compared to APGE's ROE of -0.33%. Regarding short-term risk, CMPX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check APGE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
CMPX vs IMVT Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while IMVT trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas IMVT's P/E ratio is -15.01. In terms of profitability, CMPX's ROE is -0.40%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, CMPX is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check IMVT's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
CMPX vs CERE Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CERE's P/E ratio is -16.47. In terms of profitability, CMPX's ROE is -0.40%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CMPX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
CMPX vs PCVX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while PCVX trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas PCVX's P/E ratio is -8.07. In terms of profitability, CMPX's ROE is -0.40%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, CMPX is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check PCVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
CMPX vs MTSR Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CMPX's ROE is -0.40%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, CMPX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
CMPX vs IBRX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while IBRX trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas IBRX's P/E ratio is -8.22. In terms of profitability, CMPX's ROE is -0.40%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, CMPX is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
CMPX vs RYTM Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while RYTM trades at $106.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas RYTM's P/E ratio is -33.91. In terms of profitability, CMPX's ROE is -0.40%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, CMPX is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check RYTM's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
CMPX vs MIRM Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, MIRM has a market cap of 7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while MIRM trades at $114.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas MIRM's P/E ratio is -8.39. In terms of profitability, CMPX's ROE is -0.40%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, CMPX is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
CMPX vs COGT Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, COGT has a market cap of 6.9B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while COGT trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas COGT's P/E ratio is -19.17. In terms of profitability, CMPX's ROE is -0.40%, compared to COGT's ROE of -0.83%. Regarding short-term risk, CMPX is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check COGT's competition here
Merus N.V. (NASDAQ: MRUS)
CMPX vs MRUS Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CMPX's ROE is -0.40%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, CMPX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
CMPX vs ACLX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CMPX's ROE is -0.40%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CMPX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
CMPX vs RETA Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas RETA's P/E ratio is -66.29. In terms of profitability, CMPX's ROE is -0.40%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CMPX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check RETA's competition here
Erasca, Inc. (NASDAQ: ERAS)
CMPX vs ERAS Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ERAS trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ERAS's P/E ratio is -20.29. In terms of profitability, CMPX's ROE is -0.40%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, CMPX is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
CMPX vs CGON Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CGON trades at $73.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CGON's P/E ratio is -31.55. In terms of profitability, CMPX's ROE is -0.40%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CMPX is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CGON's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
CMPX vs XENE Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, XENE has a market cap of 6.4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while XENE trades at $65.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas XENE's P/E ratio is -14.00. In terms of profitability, CMPX's ROE is -0.40%, compared to XENE's ROE of -0.49%. Regarding short-term risk, CMPX is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check XENE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
CMPX vs BLTE Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while BLTE trades at $158.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas BLTE's P/E ratio is -84.72. In terms of profitability, CMPX's ROE is -0.40%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, CMPX is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check BLTE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
CMPX vs PTCT Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, PTCT has a market cap of 6.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while PTCT trades at $75.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas PTCT's P/E ratio is -32.53. In terms of profitability, CMPX's ROE is -0.40%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, CMPX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
CMPX vs CNTA Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CMPX's ROE is -0.40%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CMPX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
CMPX vs LGND Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while LGND trades at $297.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas LGND's P/E ratio is 35.67. In terms of profitability, CMPX's ROE is -0.40%, compared to LGND's ROE of +0.16%. Regarding short-term risk, CMPX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CMPX vs SRRK Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while SRRK trades at $48.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas SRRK's P/E ratio is -13.63. In terms of profitability, CMPX's ROE is -0.40%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, CMPX is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
CMPX vs CDTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CMPX's ROE is -0.40%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, CMPX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
CMPX vs ABCM Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CMPX's ROE is -0.40%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CMPX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
CMPX vs ISEE Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CMPX's ROE is -0.40%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CMPX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
CMPX vs TVTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while TVTX trades at $56.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas TVTX's P/E ratio is -257.64. In terms of profitability, CMPX's ROE is -0.40%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, CMPX is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
CMPX vs APLS Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas APLS's P/E ratio is 38.35. In terms of profitability, CMPX's ROE is -0.40%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CMPX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check APLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
CMPX vs TERN Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas TERN's P/E ratio is -51.41. In terms of profitability, CMPX's ROE is -0.40%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CMPX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
CMPX vs DFTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while DFTX trades at $42.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas DFTX's P/E ratio is N/A. In terms of profitability, CMPX's ROE is -0.40%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, CMPX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for CMPX.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
CMPX vs MANE Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while MANE trades at $111.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas MANE's P/E ratio is -35.45. In terms of profitability, CMPX's ROE is -0.40%, compared to MANE's ROE of -0.84%. Regarding short-term risk, CMPX is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
CMPX vs FOLD Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CMPX's ROE is -0.40%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CMPX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check FOLD's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
CMPX vs CRSP Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CRSP trades at $46.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CRSP's P/E ratio is -9.15. In terms of profitability, CMPX's ROE is -0.40%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, CMPX is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CRSP's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
CMPX vs AKRO Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CMPX's ROE is -0.40%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, CMPX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check AKRO's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
CMPX vs EWTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while EWTX trades at $41.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas EWTX's P/E ratio is -25.06. In terms of profitability, CMPX's ROE is -0.40%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, CMPX is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check EWTX's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
CMPX vs ALPN Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CMPX's ROE is -0.40%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CMPX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ALPN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
CMPX vs CAI Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CAI trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CAI's P/E ratio is -85.97. In terms of profitability, CMPX's ROE is -0.40%, compared to CAI's ROE of +0.06%. Regarding short-term risk, CMPX is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
CMPX vs DNTH Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while DNTH trades at $104.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas DNTH's P/E ratio is -25.30. In terms of profitability, CMPX's ROE is -0.40%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, CMPX is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
CMPX vs ACAD Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ACAD trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ACAD's P/E ratio is 12.45. In terms of profitability, CMPX's ROE is -0.40%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, CMPX is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
CMPX vs DYN Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, DYN has a market cap of 4.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while DYN trades at $25.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas DYN's P/E ratio is -7.96. In terms of profitability, CMPX's ROE is -0.40%, compared to DYN's ROE of -0.58%. Regarding short-term risk, CMPX is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check DYN's competition here
Opthea Limited (NASDAQ: OPT)
CMPX vs OPT Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas OPT's P/E ratio is -1.52. In terms of profitability, CMPX's ROE is -0.40%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CMPX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
CMPX vs MRTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CMPX's ROE is -0.40%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CMPX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check MRTX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
CMPX vs VKTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas VKTX's P/E ratio is -8.42. In terms of profitability, CMPX's ROE is -0.40%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, CMPX is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
CMPX vs CELC Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CELC has a market cap of 4B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CELC trades at $82.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CELC's P/E ratio is -21.09. In terms of profitability, CMPX's ROE is -0.40%, compared to CELC's ROE of -2.45%. Regarding short-term risk, CMPX is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
CMPX vs CPRX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CPRX's P/E ratio is 12.30. In terms of profitability, CMPX's ROE is -0.40%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CMPX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
CMPX vs ELVN Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ELVN trades at $52.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ELVN's P/E ratio is -31.58. In terms of profitability, CMPX's ROE is -0.40%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, CMPX is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
CMPX vs RYZB Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CMPX's ROE is -0.40%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CMPX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check RYZB's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
CMPX vs DNLI Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while DNLI trades at $23.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas DNLI's P/E ratio is -8.18. In terms of profitability, CMPX's ROE is -0.40%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, CMPX is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check DNLI's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
CMPX vs CBAY Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CMPX's ROE is -0.40%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CMPX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check CBAY's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
CMPX vs NAMSW Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while NAMSW trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas NAMSW's P/E ratio is -10.75. In terms of profitability, CMPX's ROE is -0.40%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, CMPX is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
CMPX vs ADPT Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while ADPT trades at $22.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas ADPT's P/E ratio is -41.74. In terms of profitability, CMPX's ROE is -0.40%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, CMPX is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check ADPT's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
CMPX vs LEGN Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while LEGN trades at $19.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas LEGN's P/E ratio is -28.34. In terms of profitability, CMPX's ROE is -0.40%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, CMPX is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for CMPX.Check LEGN's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
CMPX vs SWTX Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CMPX's ROE is -0.40%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, CMPX is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
CMPX vs NAMS Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while NAMS trades at $30.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas NAMS's P/E ratio is -19.01. In terms of profitability, CMPX's ROE is -0.40%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, CMPX is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check NAMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
CMPX vs RCUS Comparison July 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMPX stands at 374.6M. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, CMPX is priced at $2.08 on the NASDAQ, while RCUS trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMPX currently has a P/E ratio of -5.07, whereas RCUS's P/E ratio is -8.56. In terms of profitability, CMPX's ROE is -0.40%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, CMPX is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for CMPX.Check RCUS's competition here